Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL HL Update 2021 | Response biomarkers in HL

Sven Borchmann • 12 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma

Sven Borchmann, MD, University of Cologne, Cologne, Germany, discusses the genetics of classical Hodgkin lymphoma (HL) and the use of biomarkers as a response marker, as discussed at the virtual Update on Hodgkin Lymphoma organized by the International Symposium on Hodgkin Lymphoma (ISHL). Dr Borchmann highlights the potential of circulating tumor DNA and protein-based biomarkers that can be used alongside PET imaging to determine a patient’s response to treatment in clinical practice and trial settings. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Sven Borchmann

1:17
The importance of risk-adapted therapies in Hodgkin lymphoma
Sven Borchmann • 15 Jun 2023
1:27
Challenges in understanding the genomic landscape of Hodgkin lymphoma
Sven Borchmann • 15 Jun 2023
0:53
The current state of MRD in Hodgkin lymphoma
Sven Borchmann • 15 Jun 2023
1:47
Using peripheral blood ctDNA-sequencing for PCNSL risk profiling
Sven Borchmann • 10 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals